Dube Eric M
SEC CIK 1763494 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | CEO, Dir | 541.4K | — | $45.35M | 40 | 2021-08-13 | 2026-09-15 |
Most active insiders at TVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Dube Eric M | CEO, Dir | — | $41.35M |
| 2 | Heerma Peter | EVP, Chief COMMERCIAL Off | — | $18.97M |
| 3 | ROTE WILLIAM E. | Chief Research Off | — | $16.43M |
| 4 | REED ELIZABETH E | CLO, GC | — | $7.02M |
| 5 | Inrig Jula | EVP, CMO, Head of R, D | — | $5.16M |
| 6 | Cline Christopher R. | CFO | — | $4.64M |
| 7 | Calvin Sandra | SVP, CAO | — | $4.19M |
| 8 | Baynes Roy D. | Dir | — | $2.55M |
| 9 | Meckler Jeffrey A | Dir | — | $1.71M |
| 10 | Coughlin Timothy | Dir | — | $1.27M |
Transactions 40
Purchase Sale Sale after option exercise All abbreviations
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 21:31 | 2026-09-15+ | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | M - OptEx | $23.34 | +400.0K | 541.4K | +283% | +$9.34M |
| DMT | 2026-09-17 21:31 | 2026-09-15+ | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale+OE | $63.48 | -400.0K | 432.9K | -48% | -$25.39M |
| DT | 2026-05-06 20:00 | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | M - OptEx | $0.00 | +22.5K | 455.4K | +5% | $0 |
| DT | 2026-05-06 20:00 | 2026-05-06 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale+OE | $43.95 | -22.5K | 432.9K | -5% | -$988.9K |
| T | 2026-04-15 21:48 | 2026-04-13 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +64.0K | 496.9K | +15% | $0 |
| MT | 2026-04-15 21:48 | 2026-04-15 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $41.09 | -64.0K | 432.9K | -13% | -$2.63M |
| DT | 2026-04-02 17:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | M - OptEx | $15.46 | +60.0K | 492.9K | +14% | +$927.6K |
| DMT | 2026-04-02 17:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale+OE | $30.93 | -60.0K | 432.9K | -12% | -$1.86M |
| D | 2026-02-24 | 2026-02-20 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | M - OptEx | $15.46 | +60.0K | 492.9K | +14% | +$927.6K |
| D | 2026-02-24 | 2026-02-20 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale+OE | $30.10 | -60.0K | 432.9K | -12% | -$1.81M |
| DM | 2026-02-03 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $32.28 | -100.1K | 466.5K | -18% | -$3.23M |
| D | 2026-02-03 | 2026-01-31 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +113.8K | 533.0K | +27% | $0 |
| DM | 2026-01-27 | 2026-01-23+ | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale+OE | $30.09 | -60.0K | 419.2K | -13% | -$1.81M |
| DM | 2026-01-27 | 2026-01-23+ | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | M - OptEx | $15.46 | +60.0K | 427.3K | +16% | +$927.6K |
| DM | 2025-10-30 | 2025-10-28+ | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale+OE | $30.32 | -120.0K | 419.2K | -22% | -$3.64M |
| DM | 2025-10-30 | 2025-10-28+ | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | M - OptEx | $15.46 | +120.0K | 446.3K | +37% | +$1.86M |
| D | 2025-05-05 | 2025-05-02 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | M - OptEx | — | +18.9K | 438.1K | +5% | — |
| D | 2025-05-05 | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale+OE | $21.05 | -18.9K | 419.2K | -4% | -$398.4K |
| 2025-02-12 | 2025-02-11 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $24.04 | -11.4K | 419.2K | -3% | -$273.5K | |
| D | 2025-02-04 | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $20.21 | -50.7K | 430.5K | -11% | -$1.02M |
| D | 2025-02-04 | 2025-01-31 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +130.0K | 481.2K | +37% | $0 |
| 2025-01-23 | 2025-01-22 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $19.46 | -10.7K | 351.2K | -3% | -$208.9K | |
| 2024-09-09 | 2024-09-05 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +32.5K | 383.1K | +9% | $0 | |
| 2024-09-09 | 2024-09-09 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $11.52 | -21.1K | 362.0K | -6% | -$243.4K | |
| D | 2024-02-02 | 2024-01-31 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +135.0K | 369.7K | +58% | $0 |
| DM | 2024-02-02 | 2024-02-01 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $8.70 | -19.1K | 360.6K | -5% | -$166.4K |
| 2024-01-25 | 2024-01-23 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $8.96 | -7,873 | 234.7K | -3% | -$70.5K | |
| 2023-09-05 | 2023-09-05 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $14.71 | -4,455 | 242.6K | -2% | -$65.5K | |
| 2023-09-05 | 2023-08-31 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +9,900 | 247.1K | +4% | $0 | |
| D | 2023-02-02 | 2023-01-31 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +97.5K | 245.3K | +66% | $0 |
| D | 2023-02-02 | 2023-02-01 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $22.25 | -8,196 | 237.2K | -3% | -$182.4K |
| 2023-01-26 | 2023-01-24 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $21.50 | -6,442 | 147.8K | -4% | -$138.5K | |
| 2023-01-06 | 2023-01-05 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $20.75 | -5,625 | 154.3K | -4% | -$116.7K | |
| 2022-02-11 | 2022-02-10 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $27.84 | -4,832 | 159.9K | -3% | -$134.5K | |
| D | 2022-02-02 | 2022-01-31 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +37.8K | 169.6K | +29% | $0 |
| D | 2022-02-02 | 2022-01-31 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $27.40 | -4,813 | 164.7K | -3% | -$131.9K |
| 2022-01-26 | 2022-01-24 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $24.98 | -7,873 | 131.7K | -6% | -$196.7K | |
| M | 2022-01-06 | 2022-01-04+ | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $30.08 | -17.3K | 141.7K | -11% | -$521.4K |
| 2021-08-17 | 2021-08-17 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | S - Sale | $17.12 | -7,836 | 156.9K | -5% | -$134.2K | |
| 2021-08-17 | 2021-08-13 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +17.5K | 164.8K | +12% | $0 |